Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

MAY 6, 2021

EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).… … Read More.

Clinical Trials 59

Clinical Trials Therapy Programs Medicine 59

Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product.

CBD 105

CBD Clinical Trials Programs Medicine 105

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. Remember, the pharmaceutical model is “this medicine addresses this specific target.”

Cannabinoids 216

Cannabinoids Sleep Clinical Trials CBD 216

Cannabis Law Report

JUNE 11, 2021

NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Here’s the press release.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 145

Law Legalization Clinical Trials CBD 145

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

MGC Pharma

FEBRUARY 20, 2018

CBD passes Stage 3 clinical trial for the treatment of epilepsy in children A study published last year in The New England Journal of Medicine saw scientists studying the effects of CBD on epileptic seizures in patients with Dravet syndrome, a severe epileptic disorder leading to frequent and uncontrollable seizures in children.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

MAY 10, 2022

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. 11 May 2022.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Puff Puff Post

OCTOBER 3, 2019

In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis. Leading the pilot research project is Dr. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Cannabis Law Report

JULY 24, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. “The It is our belief that the tailoring of the properties of these compounds will vastly improve their utility to medicine and therapy.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

SEPTEMBER 1, 2021

CYBN ) is a Toronto-based psychedelic medicine firm. The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. At the moment, MindMed is hands-down the industry leader in LSD-inspired medicines.

Research and Development 102

Research and Development Clinical Trials Therapy Pharmaceutical 102

Cannabis Law Report

JUNE 23, 2021

. “Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. David Nutt), starts in Q4 2021.

Clinical Trials 85

Clinical Trials Therapy Research and Development Treatment 85

Cannabis Law Report

MAY 10, 2022

More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. territories. This means that U.S.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Veriheal

MAY 26, 2022

But one area of cannabis medicine is still lagging behind—research. states pass relevant legislation and educating doctors about the power of cannabis medicine. In addition to the large uptick in registrants, we saw an even larger influx of new visitors to our site, enabling them to learn more about our research program.”.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Veriheal

JULY 7, 2023

Thankfully, a team of scientists at Medicinal Genomics may have just stumbled upon a solution. Medicinal Genomics stumbled upon the discovery that purple-colored cannabis plants appear to have a resistance to HLVd. Canada, and Israel are all conducting clinical trials on psychedelic treatments. Currently, the U.S.,

Legalization 97

Legalization Clinical Trials Research and Development History 97

Cannabis Law Report

AUGUST 17, 2021

The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for rare disorders that affect fewer than 200,000 people in the U.S. Conference Call and Webcast Details.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

MARCH 2, 2020

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. In lockstep with the FDA’s more open-minded approach toward psychedelic medicine, Denver, Oakland, and Santa Cruz all decided to decriminalize magic mushrooms. Hundreds of other U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Veriheal

JUNE 29, 2021

Plant medicines and concoctions made from them have been utilized throughout the history of cultures around the world. In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Cannabis Law Report

JULY 28, 2021

However, prior to committing to a substantial clinical program for that indication, PharmaDrug looked to further expand on the body of existing supportive data for esophageal cancer, while also potentially revealing new, promising cancer indications. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

AUGUST 10, 2022

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression. Optimi Health Corp.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

JUNE 4, 2021

The poster presentation of the data was by Dr. Scott Tagawa , a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. Clinical trial information: NCT03276572 ( [link] ). The full ASCO meeting program is available at: www.asco.org.

Data 100

Data Research and Development Clinical Trials Therapy 100

LifeCannMD

MAY 27, 2025

It was personal, powerful, and it changed how thousands of us think about plant medicine. Ways to save money: First-time patient discounts at dispensaries Compassionate care programs for low-income families Loyalty programs and regular sales Payment plans for larger purchases Why Legal Matters More Than You Think Look, I get it.

CBD 52

CBD Oil Epilepsy Sleep 52

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. Legislation to legalize the medicinal use of marijuana for dogs, cats and other pets in New York State is pending in the Assembly (A. Additionally, a bipartisan coalition of U.S.

Legislation 192

Legislation Decriminalization Access Therapy 192

Cannabis Law Report

JULY 13, 2022

“Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

FEBRUARY 24, 2022

Thus, providing a new pathway for patients to access psychedelic treatment, and another example of the medicinal approach to psychedelic legalization. Timeline of Medicinal Legalization in Canada. The changes to the FDR and CDSA do not outright legalize MDMA or psilocybin for medicinal use. Subsection 56(1) Exemption.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 25, 2021

“The acquisition of a distinctive company like Lucid illustrates FSD Pharma’s vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative diseases in a new way,” said Anthony Durkacz, Interim CEO of FSD Pharma. Strategic Highlights.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

DECEMBER 9, 2021

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. in the latter part of 2022, after the Phase 1 trial has been completed. Dr. Anthony Rudd.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

SpeedWeed

AUGUST 11, 2021

“This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday. The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. MAPS Makes History.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

NOVEMBER 13, 2019

Denmark is already leading the way by launching a Big Pharma modelled 4-year medical marijuana trial in early 2018, following a unanimous vote in Parliament. They are learning quickly from the successes and failures in Canada’s legal medical cannabis program that has been active since 2001. Arundati Dandapani.

Clinical Trials 78

Clinical Trials Research and Development Cultivation Patients 78

Cannabis Law Report

OCTOBER 20, 2021

The CBD brand FullSend claims Nelk has conducted an “enforcement program” to put it out of business by threatening it with litigation and demanding it stop selling and advertising its products under what FullSend claims is its own mark. In response, they argued the VA Medicinal Cannabis Research Act ( H.R. According to Calif.’s

Hemp 52

Hemp Clinical Trials CBD Legalization 52

Cannabis Law Report

OCTOBER 22, 2021

Medicines and Healthcare products Regulatory Agency (the “ MHRA ”), Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate from its pipeline of N,N-dimethyltryptamine (“ DMT ”) assisted therapies for the treatment of major depressive disorder (“ MDD ”). For further information contact: .

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52